[Supplementary Announcement Overview](index=1&type=section&id=%E8%A3%9C%E5%85%85%E5%85%AC%E5%91%8A%E6%A6%82%E8%BF%B0) This announcement supplements the 2024 annual report and prior announcements, providing additional details on Placing A and B proceeds and the new share option scheme - This announcement further supplements the 2024 annual report and previous supplementary announcements[4](index=4&type=chunk) - The supplementary content primarily concerns the use of proceeds from Placing A and Placing B and the new share option scheme[4](index=4&type=chunk) [Use of Proceeds](index=1&type=section&id=%E6%89%80%E5%BE%97%E6%AC%BE%E9%A0%85%E7%94%A8%E9%80%94) Net proceeds from Placing A and B were fully utilized for general working capital, consistent with previously disclosed purposes - The net proceeds from Placing A and Placing B have been fully utilized for the Group's **general working capital**[5](index=5&type=chunk) - The use of proceeds aligns with the purposes disclosed in the company's announcements on January 15, 2024, and August 26, 2024[5](index=5&type=chunk) [New Share Option Scheme](index=1&type=section&id=%E6%96%B0%E8%B3%BC%E8%82%A1%E6%AC%8A%E8%A8%88%E5%8A%83) The new share option scheme, adopted in November 2024, specifies the number of options available for grant and clarifies the revised maximum new shares to be issued - The new share option scheme was adopted on **November 19, 2024**[6](index=6&type=chunk) [Number of Share Options Available for Grant](index=1&type=section&id=%E6%96%B0%E8%B3%BC%E8%82%A1%E6%AC%8A%E8%A8%88%E5%8A%83%E9%A0%85%E4%B8%8B%E5%8F%AF%E4%BE%9B%E6%8E%88%E5%87%BA%E7%9A%84%E8%B3%BC%E8%82%A1%E6%AC%8A%E6%95%B8%E7%9B%AE) As of December 31, 2024, the number of share options available for grant under the new scheme is specified, with none available at year-start - As of January 1, 2024, no share options were available for grant under the scheme mandate limit or the service provider sub-limit[6](index=6&type=chunk) Number of Share Options Available for Grant under New Share Option Scheme as of December 31, 2024 | Item | Number of Share Options (shares) | | :--- | :--- | | Scheme Mandate Limit | 14,535,748 | | Service Provider Sub-limit | 4,360,724 | [Maximum Number of New Shares to be Issued](index=2&type=section&id=%E6%96%B0%E8%B3%BC%E8%82%A1%E6%AC%8A%E8%A8%88%E5%8A%83%E9%A0%85%E4%B8%8B%E5%B0%87%E4%BA%88%E7%99%BC%E8%A1%8C%E6%96%B0%E8%82%A1%E4%BB%BD%E7%9A%84%E6%95%B8%E7%9B%AE%E4%B8%8A%E9%99%90) The Board clarified and revised a clerical error regarding the maximum number of new shares to be issued under the new share option scheme - The Board clarified a clerical error in the supplementary announcement regarding the maximum number of new shares to be issued under the new share option scheme[8](index=8&type=chunk) Revision to Maximum Number of New Shares to be Issued under New Share Option Scheme | Metric | Before Revision | After Revision | | :--- | :--- | :--- | | Maximum New Shares | Not applicable (clerical error) | 14,535,748 shares | | Percentage of Existing Issued Share Capital | Approximately 10.0% | Approximately 9.4% | | Existing Issued Share Capital | 145,357,480 shares | 154,757,480 shares |

Group 1 - The core point of the article is that Ying Sheng Science (00209) has completed a placement agreement, issuing a total of 30.95 million shares at a price of HKD 0.35 per share, which represents approximately 16.67% of the company's expanded issued share capital as of the announcement date [1][1][1] - On September 19, shareholders deposited shares into Imagi Brokerage Limited, with a market value of HKD 8.9759 million, accounting for 20% [1][1][1] - All conditions outlined in the placement agreement have been met, and the placement was completed according to the terms and conditions of the agreement [1][1][1]

Group 1 - The core point of the article is that Ying Sheng Science has completed a placement agreement, issuing shares at a price of HKD 0.35 per share, which represents approximately 16.67% of the company's expanded issued share capital [1][1][1] Group 2 - On September 19, shareholders of Ying Sheng Science deposited shares into Imagi Brokerage Limited, with a total market value of HKD 8.9759 million, accounting for 20% [1][1][1] - The company has issued a total of 30.9515 million placement shares to no fewer than six subscribers [1][1][1]

Group 1 - The company Ying Sheng Science (00209.HK) announced the issuance of 30.95 million shares under a placement agreement, with an issue price of HKD 0.35 per share [1]

如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | | 是 | | | | 證券代號 (如上市) 00209 | 說明 | | 根據一般授權配售新股份 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | | 每股發行/出售價 (註4) | 已發行股份總數 | | | 於下列 ...

Core Viewpoint - The company, Ying Sheng Science (00209), has successfully completed a placement agreement, issuing a total of 30.9515 million shares at a price of HKD 0.35 per share, which represents approximately 16.67% of the company's enlarged issued share capital as of the announcement date [1]. Group 1 - The placement agreement conditions have all been met, and the placement was completed on September 19, 2025 [1]. - The company issued shares to no fewer than six placees [1]. - The placement price per share was set at HKD 0.35 [1].

Group 1 - The core point of the article is that Ying Sheng Science (00209) has completed a placement agreement, issuing a total of 30.9515 million shares at a price of HKD 0.35 per share, which represents approximately 16.67% of the company's issued share capital after the placement [1] Group 2 - The placement was completed on September 19, 2025, and all conditions outlined in the placement agreement have been met [1] - The shares were allocated to no fewer than six subscribers [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示不會就本公告全部或任何部份內容而產 生或因依賴該等內容而引致之任何損失承擔任何責任。 本公告僅供參考用途，並不構成收購、購買或認購本公司任何證券之邀請或要約。 WINSHINE SCIENCE COMPANY LIMITED 209 完成根據一般授權配售新股份 配售代理 完成根據一般授權配售新股份 董事會欣然宣佈，配售協議所載的所有條件均已達成，且配售事項已於二零二五年九月 十九日根據配售協議的條款及條件完成（「完成」）。根據配售協議，本公司已按每股配售 股份0.35港元之配售價，向不少於六名承配人配發及發行合共30,951,496股配售股份，相 當於本公告日期本公司已發行股本（經配發及發行配售股份擴大後）約16.67%。 - 1 - * 所得款項用途 配售事項的所得款項總額為10,833,023.60港元，扣除費用及開支後，配售事項的所得款項 淨額約為10,320,000.00港元。配售事項所得款項淨額擬作以下用途：(i)約50%用於償還貸 款；(ii)約10%用於支付未清償核數費用；(i ...

Group 1 - The core point of the article is that Ying Sheng Science (00209) has engaged in a share placement agreement, raising approximately HKD 10.83 million through the issuance of new shares at a price of HKD 0.350 per share [1] - On September 16, shareholders transferred shares worth HKD 3.7261 million from Hope Securities to Bank of China (Hong Kong), representing 8.45% of the total shares [1] - The share placement involves issuing 30.9515 million new shares, which accounts for about 16.67% of the company's total issued shares post-placement [1] Group 2 - The estimated net proceeds from the placement, after deducting all related expenses, are approximately HKD 10.32 million [1] - The company plans to allocate around 50% of the net proceeds for loan repayment and the other 50% for operational funds and general corporate purposes [1]

配售股份的总面值将为30.95万港元。配售事项的所得款项总额将为1083.3万港元。经扣除所有相关开支 后，配售事项的所得款项净额估计约为1032万港元，其约50%拟用作偿还贷款，及约50%拟用作集团营 运资金及一般企业用途。 9月11日，瀛晟科学发布公告，于当日交易时段后，公司与配售代理订立配售协议，据此，配售代理同 意按悉数包销基准按每股配售股份0.350港元的价格为及代表公司向不少于六名承配人配售3095.15万股 新股份，占经配售事项扩大后公司已发行股份总数约16.67%。配售股份将根据一般授权配发及发行。 香港联交所最新资料显示，9月16日，瀛晟科学(00209)股东将股票由希望证券转入中国银行(香港)，转 仓市值372.61万港元，占比8.45%。 ...